Bliss GVS Pharma Reaches 52-Week High of Rs. 181.35 with 42.53% Annual Return

Bliss GVS Pharma, a small-cap player in the pharmaceuticals and drugs industry, has recently reached a new 52-week high of Rs. 181.35 on January 1, 2025. The stock has shown strong performance, outperforming its sector by 7.79% today. Over the past six days, Bliss GVS Pharma has experienced consecutive gains, accumulating a total return of 11.29%.

The stock’s intraday high of Rs. 181.35 reflects a 10.14% increase for the day. Additionally, Bliss GVS Pharma is currently trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend in its price movement.

In terms of annual performance, Bliss GVS Pharma has delivered a notable return of 42.53% over the past year, significantly outpacing the Sensex, which has recorded an 8.20% increase during the same period. The stock’s recent performance highlights its resilience and growth within the competitive pharmaceuticals sector.

Related Posts

‘Made in India’ Surgical Robot SSI Mantra’s Hallowed NASDAQ Moment in New York

New Delhi: It was a hallowed moment of pride for surgical robot SSI Mantra, its architect and robotic surgery wizard Dr Sudheer Srivastava, entire Indian Medtech Industry and ‘Make in…

  • Pharma
  • June 4, 2025
  • 40 views
Zydus to acquire 2 biologics manufacturing units in U.S. from Agenus for $125 million

Zydus Lifesciences plans to acquire Nasdaq-listed clinical-stage immuno-oncology firm Agenus’s two biologics manufacturing facilities in California, U.S. for $125 million to enter the global biologics contract development and manufacturing organization…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

‘Made in India’ Surgical Robot SSI Mantra’s Hallowed NASDAQ Moment in New York

‘Made in India’ Surgical Robot SSI Mantra’s Hallowed NASDAQ Moment in New York

Zydus to acquire 2 biologics manufacturing units in U.S. from Agenus for $125 million

Zydus to acquire 2 biologics manufacturing units in U.S. from Agenus for $125 million

Ananda Pharma advances CBD drug with Phase 1 study listing

Ananda Pharma advances CBD drug with Phase 1 study listing

With Advent of Level Playing Field, Domestic MedTech Industry exclaims ‘Eureka!’

With Advent of Level Playing Field, Domestic MedTech Industry exclaims ‘Eureka!’